Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible

catheter robotics and the developer of robotic technology for accurate

3D control of catheter movement, today announced changes to its board

of directors. Effective immediately, Michael L. Eagle has been

appointed as a Director, following the resignation of Joseph M.

Mandato as a Director.

"Mike's extensive global experience in the medical device and

pharmaceutical industries provides Hansen with tremendous operational

and commercial expertise as we continue to launch our vascular

platform and execute our strategy," remarked Bruce Barclay, President

and Chief Executive Officer. "Additionally, I would like to thank Joe

for his significant contributions to the Company over the past six


Mr. Eagle has a rich history of operational, commercial and

manufacturing experience. He served as Vice President of Global

Manufacturing for Eli Lilly and Company from 1994 to 2001. During his

tenure, he was responsible for global production, quality,

engineering, facilities, distribution, environmental conditions and

safety. Mr. Eagle joined Lilly in 1983 when Lilly acquired Advanced

Cardiovascular Systems where he was Sr. Vice President of Operations.

Later he served as President and CEO of IVAC Corporation and Vice

President of the Vascular Intervention, Medical Devices and

Diagnostics Division where he oversaw the operations of four medical

device subsidiaries, a technology development center and the medical

device and diagnostics businesses in Japan. He served as Vice

President of Pharmaceutical Manufacturing prior to his most recent


Prior to his term at Lilly, Mr. Eagle was General Manager of Plastics

Processing at IMED Corporation. Since retiring from Lilly, he has

served as the founding member of Barnard Life Sciences, LLC -- a

healthcare consulting company.

Mr. Eagle has served as a Director of a number of boards of both

public and private healthcare companies including Micrus Endovascular,

Inc. and Perclose, Inc. He currently serves on the boards of Cadence

Pharmaceuticals and Somaxon Pharmaceuticals.

"I am pleased to join the Hansen board at such an important time for

the company. I look forward to assisting the company in its mission to

become the global leader in flexible robotics," commented Mr. Eagle on

his appointment.

About Hansen Medical, Inc.

Hansen Medical, Inc., based in Mountain View, California, develops

products and technology using robotics for the accurate positioning,

manipulation and control of catheters and catheter-based technologies.

The Company's Sensei@ X Robotic Catheter System and Artisan Control

Catheter were cleared by the U.S. Food and Drug Administration for

manipulation and control of certain mapping catheters in

electrophysiology (EP) procedures. This robotic catheter system is

compatible with fluoroscopy, ultrasound, 3D surface map and patient

electrocardiogram data. In the United States, the Sensei System is not

approved for use in guiding ablation procedures; this use remains

experimental. The U.S. product labeling therefore provides that the

safety and effectiveness of the Sensei X System and Artisan Control

Catheter for use with cardiac ablation catheters in the treatment of

cardiac arrhythmias, including atrial fibrillation (AF), have not been

established. In the European Union, the Sensei X System and Artisan

Control Catheter are cleared for use during EP procedures, such as

guiding catheters in the treatment of AF, and the Lynx@ Robotic

Ablation Catheter is cleared for the treatment of AF. The Company's

Magellan Robotic System, NorthStar Robotic Catheter and related

accessories, which are intended to facilitate navigation to anatomical

targets in the peripheral vasculature and subsequently provide a

conduit for manual placement of therapeutic devices, have undergone

conformity assessment and CE marking and are commercially available in

the European Union. In the U.S., the Magellan Robotic System, the

NorthStar Robotic Catheter and accessories are the subject of a

current filing with the FDA and are not commercially available.

Additional information can be found at

Forward-Looking Statements

This press release contains forward-looking statements regarding,

among other things, statements relating to goals, plans, expectations,

objectives, milestones and future events. All statements, other than

statements of historical fact, are statements that could be deemed

forward-looking statements, including statements containing the words

"plan," "expects," "potential," "believes," goal," "estimate,"

"anticipates," and similar words. These statements are based on the

current estimates and assumptions of our management as of the date of

this press release and are subject to risks, uncertainties, changes in

circumstances and other factors that may cause actual results to

differ materially from the information expressed or implied by

forward-looking statements made in this press release. Examples of

such statements include statements about the potential timing of FDA

clearance of our Magellan Robotic System in the US, the potential

benefits of our Magellan Robotic System on the vascular procedures and

the timing of commercializing our Magellan Robotic System, and

anticipated growth in the adoption of the Sensei platform for

electrophysiology procedures. Important factors that could cause

actual results to differ materially from those indicated by such

forward-looking statements include, among others: engineering,

regulatory and sales challenges in developing new products and

entering new markets; potential safety and regulatory issues that

could slow or suspend our sales; the uncertain timelines, costs and

results of pre-clinical and clinical trials; the rate of adoption of

our systems and the rate of use of our catheters; the scope and

validity of intellectual property rights applicable to our products;

competition from other companies; our ability to recruit and retain

key personnel; our ability to maintain our remedial actions over

previously reported material weaknesses in internal controls over

financial reporting; the effect of credit, financial and economic

conditions on capital spending by our potential customers; our ability

to manage expenses and obtain additional financing; and other risks

more fully described in the "Risk Factors" section of our Quarterly

Report on Form 10-Q for the quarter ended September 30, 2011 filed

with the SEC on November 7, 2011 and the risks discussed in our other

reports filed with the SEC. Given these uncertainties, you should not

place undue reliance on the forward-looking statements in this press

release. We undertake no obligation to revise or update information

herein to reflect events or circumstances in the future, even if new

information becomes available.

Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart

Design), and Sensei are registered trademarks of Hansen Medical, Inc.

in the United States and other countries.